Main Article Content
. Penston, J. (2010). Stats.con – How we’ve been fooled by statistics-based research in medicine. The London Press.
. Elwood, J.M. (1988). Causal relationships in medicine. Oxford: Oxford University Press.
. Rothwell, P.M. (2005). Treating individuals 1: External validity of randomised controlled trials: “To whom do the results of this trial apply?” Lancet 365, 82-93.
. Fuks, A., Weijer, C., Freedman, B., Shapiro, S., Skrutkowska, M. and Riaz, A. (1998). A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. Journal of Clinical Epidemiology 51, 69-79.
. Hall, J.C., Mills, B., Nguyen, H. and Hall, J.L. (1996). Methodologic standards in surgical trials. Surgery 119, 466-472.
. Shapiro, S.H., Weijer, C. and Freedman, B. (2000). Reporting the study populations of clinical trials. Clear transmission or static on the line? Journal of Clinical Epidemiology 53, 973-979.
. Wilcox, R.G. et al (1988). For the ASSET study group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 332, 525-530.
. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332, 349-360.
. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. (1992). ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339, 753-770.
. LATE Study Group. (1993). Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 342, 759-766.
. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. (1999). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354, 716-722.
. Penston, J. (2003). Fiction and fantasy in medical research. London: The London Press.
. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. (1990). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336, 65-71.
. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. (1994). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343, 1115-1122.
. Gilbody, S., Wahlbeck, K. and Adams, C. (2002). Randomised controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatrica Scandanavica 105, 243-251.
. Muller, D.W. and Topol, E.J. (1990). Selection of patients with acute myocardial infarction for thrombolytic therapy. Annals of Internal Medicine 113, 949-960.
. Haynes, R.B. and Dantes, R. (1987). Patient compliance and the conduct and interpretation of therapeutic trials. Controlled Clinical Trials 8, 12-19.
. Gomez-Marin, O., Prineas, R.J. and Sinaiko, A.R. (1991). The sodium-potassium blood pressure trial in children: design, recruitment and randomisation. Controlled Clinical Trials 12, 408-423.
. Pablos-Mendez, A., Barr, R.G. and Shea, S. (1998). Run-in periods in randomised trials: implications for the application of results in clinical practice. Journal of the American Medical Association 279, 222-225.
. Yusuf, S. et al. (2000). for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine 342, 145-153.
. Licht, R.W., Gouliaev, G., Vestergaard, P. and Frydenberg, M. (1997). Generalisability of results of randomised drug trials. British Journal of Psychiatry 170, 264-267.
. Gurwitz, J.H., Col, N.F. and Avorn, J. (1992). The exclusion of elderly and women from clinical trials in acute myocardial infarction. Journal of the American Medical Association 268, 1417-1422.
. Bjorn, M., Brendstrup, C., Karlsen, S. and Carlsen, J.E. (1998). Consecutive screening and enrolment in clinical trials: the way to representative patient samples? Journal of Cardiac Failure 4, 225-230.
. Brown, N., Melville, M., Gray, D. et al. (1999). Relevance of clinical trial results in myocardial infarction to medical practice: comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis. Heart 81, 598-602.
. Britton, A., McKee, M., Black, N., McPherson, K., Sanderson, C. and Bain, C. (1999). Threats to applicability of randomised trials: exclusions and selective participation. Journal of Health Services Research and Policy 4, 112-121.
. Moore, D.A., Goodall, R.L., Ives, N.J., Hooker, M., Gazzard, B.G. and Easterbrook, P.J. (2000). How generalisable are the results of large randomised controlled trials of antiretroviral therapy? HIV Medicine 1, 149-154.
. Woods, K.I., Ketley, D., Ludman, P.F. et al. (1999). Intravenous beta blockade in acute myocardial infarction. Doubt exists about external validity of trials of intravenous beta blockade. British Medical Journal 318, 328-329.
. Dixon, G., Boyle, R.M. and Norris, R.M. (2000). Clinical trials in acute myocardial infarction versus real life: a limitation of evidence-based medicine. British Journal of Cardiology 7, 709-711.
. Hampton, J.R. (2002). Size isn’t everything. Statistics in Medicine 21, 2807-2814.
. Jarvinen, T.L.N., Sievanen, H., Kannus, P., Jokihaara, J. and Khan, K.M. (2011). The true cost of pharmacological disease prevention. British Medical Journal 342, d2175.
. Downs, S.H., Black, N.A., Devlin, H.B., Royston, C.M. and Russell, R,C. (1996). Systematic review of the effectiveness and safety of laparascopic cholecystectomy. Annals of the Royal College of Surgeons of England 78, 241-323.
. Roberts, C. (1999). The implications of variation in outcome between health professionals for the design and analysis of randomised controlled trials. Statistics in Medicine 18, 2605-2615.
. Cohen, L.J. (1989). An introduction to the philosophy of induction and probability. Oxford: Clarendon Press.
. Best, W.R., Becktel, J.M., Singleton, J.W. and Kern, F. (1976). Development of a Crohn’s disease activity index. National Copoperative Crohn’s Disease Study. Gastroenterology 70, 439-444.
. Gotzsche, P.C. (1989). Methodology and overt and hidden bias in reports of 196 double-blind trials of non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Controlled Clinical Trials 10, 31-56.
. Thornley, B. and Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181-1184.
. Naylor, C.D., Chen, E. and Strauss, B. (1992). Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Annals of Internal Medicine 117, 916-921.
. Forrow, L., Taylor, W.C. and Arnold, R.M. (1992). Absolutely relative: how research results are summarized can affect treatment decisions. American Journal of Medicine 92, 121-124.
. Bobbio, M., Demichelis, B. and Giustetto, G. (1994). Completeness of reporting trial results: effect on physicians’ willingness to prescribe. Lancet 343, 1209-1211.
. Bucher, H.C., Weinbacher, M. and Gyr, K. (1994). Influence of method of reporting study results on decisions of physicians to prescribe drugs to lower cholesterol concentrations. British Medical Journal 309, 761-764.
. Cranney, M. and Walley, T. (1996). Same information, different decisions: the influence of evidence on the management of hypertension in the elderly. British Journal of General Practice 46, 661-663.
. Fahey, T., Griffiths, S. and Peters, T.J. (1995). Evidence based purchasing: understanding results of clinical trials and systematic reviews. British Medical Journal 311, 1056-1059.
. Malenka, D.J., Baron, J.A., Johansen, S., Wahrenberger, J.W. and Ross, J.M. (1993). The framing effect of relative and absolute risk. Journal of General Internal Medicine 8, 543-548.
. Skolbekken, J-A. (1998). Communicating the risk reduction achieved by cholesterol reducing drugs. British Medical Journal 316, 1956-1958.
. Friedmann, P.D., Brett, A.S. and Mayo-Smith, M.F. (1996). Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Annals of Internal Medicine 124, 414-421.
. Lewis, D.K., Robinson, J. and Wilkinson, E. (2003). Factors involved in deciding to start preventive treatment: qualitative study of clinicians’ and lay people’s attitudes. British Medical Journal 327, 841.
. Lewis, D.K. and Barton, S. (2003). Who decides when to start preventive treatment? A questionnaire survey to compare the views of different population subgroups.
Journal of Epidemiology and Community Health 57, 241-242.
. Steel, N. (2000). Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. British Medical Journal 320, 1446-1447.
. MacAlister, F.A., O’Connor, A.M., Wells, G., Grover, S.A. and Laupacis, A. (2000). When should hypertension be treated? The different perspectives of Canadian family physicians and patients. Canadian Medical Association Journal 163, 403-408.
. Trewby, P.N., Reddy, A.V., Trewby, C.S., Ashton, V.J., Brennan, G. and Inglis, J. (2002). Are preventive drugs preventive enough? A study of patients’ expectation of benefit from preventive drugs. Clinical Medicine 2, 527-533.
. Penston, J. (2007). Patients’ preferences shed light on the murky world of guideline-based medicine. Journal of Evaluation in Clinical Practice 13, 154-159.